Short Interest in Mustang Bio, Inc. (NASDAQ:MBIO) Declines By 22.4%

Mustang Bio, Inc. (NASDAQ:MBIO) was the recipient of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 91,700 shares, a decrease of 22.4% from the February 13th total of 118,200 shares. Based on an average daily volume of 310,600 shares, the days-to-cover ratio is currently 0.3 days. Currently, 6.4% of the shares of the company are short sold.

Mustang Bio Trading Up 0.7 %

MBIO stock traded up $0.01 on Tuesday, hitting $1.43. The company’s stock had a trading volume of 28,190 shares, compared to its average volume of 243,495. The firm has a 50 day moving average of $4.04 and a two-hundred day moving average of $8.79. Mustang Bio has a 1 year low of $1.35 and a 1 year high of $67.00. The stock has a market cap of $1.37 million, a price-to-earnings ratio of -0.02 and a beta of 1.82.

Institutional Trading of Mustang Bio

A hedge fund recently raised its stake in Mustang Bio stock. Geode Capital Management LLC raised its position in Mustang Bio, Inc. (NASDAQ:MBIO) by 15.9% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 284,437 shares of the company’s stock after buying an additional 38,951 shares during the quarter. Geode Capital Management LLC owned about 29.63% of Mustang Bio worth $50,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 9.95% of the company’s stock.

About Mustang Bio

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.